In addition to their beneficial effects on CD4+ T cells, they could also indirectly promote tumor killing by activating the complement system upon secretion of neoantigen-specific antibodies, which may recognize HLA-bound neoepitopes in vivo (40). The gene discussed is CD4; the disease is neoplasm.